All In MedTech

Device Trial Radar · NCT05934487

PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

A Prospective, Multi-Center, Open Label, Randomized Control Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class II-III Heart Failure Patients

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,750 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,750

Planned (sponsor's estimate)

Start

Nov 29, 2023

Primary completion

Sep 2028

Study completion Sep 2033

Sponsor

Lead sponsor
Endotronix, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jul 7, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class II HF patients, where patients have daily access to PAP data. * Treatment Arm (Group 1) * Active Control Arm (Group 2) * Crossover Arm (Group 3) NYHA III Cohort - To demonstrate safety and efficacy of the Cordella PA Sensor System in NYHA Class III HF patients, where patients have daily access to PAP data, including a randomized sub-study to evaluate a clinician-directed patient self-management strategy.

Conditions

  • Heart Failure NYHA Class II
  • Heart Failure NYHA Class III
  • Heart Failure

Interventions

  • Cordella™ Pulmonary Artery Sensor SystemDevice

    The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management, with the goal of reducing heart failure hospitalizations. The system comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation. Cordella Sensor Cordella Delivery System myCordella Patient Reader Reader Dock Cordella Calibration Equipment (CalEQ) myCordella Tablet Cordella Data Analysis Platform (CDAP)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy- NYHA II Cohort - A composite of first HF event or death from Cardiovascular Death up to 24 months.Time frame: 24 months
  2. Efficacy- NYHA III Cohort (Phase I) - a composite of HF events or death from cardiovascular disease at 6 monthsTime frame: 12 months
  3. Safety- Randomized Arm- Freedom from device/system related complicationTime frame: 24 months

4 more outcomes with a free account

Locations

48 sites in 3 countries. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona · Recruiting

  • USC

    Los Angeles, California · Recruiting

  • UCSF Medical Center

    San Francisco, California · Recruiting

45 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.